Share Buyback Transaction Details May 3 - 7, 2018
May 8, 2018 - Wolters Kluwer today reports that it has repurchased 220,026 of its own ordinary shares in the period from May 3, 2018 up to and including May 7, 2018 for €10.0 million and at an average share price of €45.39.
These share repurchases are part of the three-year share buyback program (2016-2018) originally announced on February 24, 2016. This buyback program includes repurchases made to offset annual incentive share issuance. The cumulative amounts repurchased under this three-year program are now as follows:
Share Buyback Program 2016-2018
| Period | Cumulative shares repurchased in period | Total consideration (€ million) | Average share price (€) |
| 2018 To Date | 4,690,034 | 200.0 | 42.64 |
| 2017 | 7,768,288 | 300.0 | 38.62 |
| 2016 | 5,826,473 | 199.7 | 34.28 |
| Total | 18,284,795 | 699.7 | 38.27 |
As stated on February 21, 2018, we intend to execute up to €400 million in share buybacks in 2018, including €200 million to mitigate the EPS dilution related to the sale of Corsearch and certain Swedish assets. In addition, following the completion of the sale of ProVation on March 9, 2018, we also intend to deploy these proceeds of this sale (approximately €150 million) towards additional share repurchases in 2018 and 2019 to mitigate the expected EPS dilution.
The third-party engagement to repurchase €150 million in shares in the period from February 23, 2018 up to and including May 7, 2018 has hereby been fulfilled.
Share repurchases are made within the limits of relevant laws and regulations, in particular Regulation (EU) 596/2014) and Wolters Kluwer's Articles of Association. Repurchased shares are added to and held as Treasury shares and will be used for capital reduction purposes or to meet obligations arising from share-based incentive plans.
Further information is available on our website:
- Download the share buyback transactions excel sheet for detailed individual transaction information.
- Weekly reports on the progress of our share repurchases.
- Overview of share buyback programs.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information, software solutions, and services for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2017 annual revenues of €4.4 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries, and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our solutions and organization, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
| Media | Investors/Analysts |
| Annemarije Dérogée-Pikaar | Meg Geldens |
| Corporate Communications | Investor Relations |
| t + 31 172 641 470 | t + 31 172 641 407 |
| [email protected] | [email protected] |
Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "shall" and similar expressions. Wolters Kluwer cautions
that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.
Attachment


Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
World game at war: why some European nations have threatened a World Cup boycott
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 



